Suberoylanilide Hydroxamic Acid in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well suberoylanilide hydroxamic acid works in treating
patients with stage IIIB, stage IV, or recurrent non-small cell lung cancer. Drugs used in
chemotherapy, such as suberoylanilide hydroxamic acid, work in different ways to stop the
growth of tumor cells, either by killing the cells or by stopping them from dividing.
Suberoylanilide hydroxamic acid may also stop the growth of tumor cells by blocking some of
the enzymes needed for cell growth.